Aducanumab, lecanemab, and donanemab are novel monoclonal antibodies designed to slow disease progression and hopefully have a positive impact in the field of Alzheimer disease management.
Angie Giglione, PharmD Candidate
Advertisement
Articles by Angie Giglione, PharmD Candidate
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Pharmacy Times
1
Operationalizing Epcoritamab-GemOx in Practice: A Focus on EPCORE NHL-2
2
Five-Year NATALEE Data Show Ribociclib Improves Outcomes in High-Risk HR+/HER2– Early Breast Cancer
3
Under Pressure: A Brief Overview of the Updated Hypertension Guidelines
4
Abemaciclib Provides Long-Term Survival Benefit in High-Risk Early Breast Cancer
5
